Townsquare Capital LLC Has $21.49 Million Stake in Pfizer Inc. (NYSE:PFE)

Townsquare Capital LLC boosted its holdings in Pfizer Inc. (NYSE:PFE) by 28.9% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 742,714 shares of the biopharmaceutical company’s stock after purchasing an additional 166,709 shares during the quarter. Townsquare Capital LLC’s holdings in Pfizer were worth $21,494,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Olistico Wealth LLC bought a new stake in shares of Pfizer during the second quarter worth about $25,000. Gladius Capital Management LP increased its holdings in Pfizer by 102.8% during the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 38,015 shares in the last quarter. MFA Wealth Advisors LLC purchased a new stake in shares of Pfizer in the second quarter worth approximately $29,000. Quarry LP bought a new position in shares of Pfizer in the second quarter valued at approximately $31,000. Finally, Financial Connections Group Inc. purchased a new position in shares of Pfizer during the second quarter valued at approximately $34,000. Institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

PFE has been the topic of several recent analyst reports. Citigroup started coverage on Pfizer in a research note on Friday, October 25th. They set a “neutral” rating and a $30.00 price objective on the stock. Barclays boosted their price target on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research note on Wednesday, October 23rd. StockNews.com downgraded Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Finally, Evercore ISI raised Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Pfizer presently has an average rating of “Moderate Buy” and an average target price of $32.92.

Insider Buying and Selling

In other news, Director Scott Gottlieb bought 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 30th. The shares were acquired at an average price of $28.24 per share, with a total value of $28,240.00. Following the acquisition, the director now owns 10,000 shares of the company’s stock, valued at approximately $282,400. The trade was a 11.11 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. 0.06% of the stock is currently owned by insiders.

Pfizer Price Performance

NYSE PFE opened at $25.76 on Wednesday. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The company has a market cap of $145.98 billion, a PE ratio of 34.81, a price-to-earnings-growth ratio of 0.83 and a beta of 0.67. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54. The firm’s 50-day simple moving average is $28.05 and its two-hundred day simple moving average is $28.54.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The company had revenue of $17.70 billion for the quarter, compared to analysts’ expectations of $14.92 billion. During the same period in the prior year, the company posted ($0.17) EPS. Pfizer’s revenue was up 31.2% compared to the same quarter last year. Research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be paid a dividend of $0.42 per share. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.52%. Pfizer’s payout ratio is 227.03%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.